Nuvalent (NUVL) Share-based Compensation (IS) (2025 - 2026)
Nuvalent's Share-based Compensation (IS) was $28.88 million in Q1 2026, up 41.7% from $20.38 million a year earlier.
Powered by 
Analysis
Nuvalent (NUVL) Share-based Compensation (IS) (2025 - 2026) Analysis & Trends
For FY2025, Share-based Compensation (IS) at Nuvalent came in at $86.5 million, up 42.8% from FY2024.
- In earlier years, Share-based Compensation (IS) was $60.58 million in FY2024 (+137.0%) and $25.56 million in FY2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | - |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | - |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | - |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | - |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | - |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | - |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 28.88 Mn |
API Access
Nuvalent Share-based Compensation (IS) API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=share-based-compensation-is&ticker=NUVL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "share-based-compensation-is", "ticker": "NUVL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=share-based-compensation-is&ticker=NUVL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();